-
-
-
-
-
-
-
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
-
-
-
-
-
-
-
Zenas BioPharma begins Phase 1 trial of oral IL-17 inhibitor ZB021
-
-
-
-
-
-
-
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
-
-
-
-
-
-
-
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
-
-
-
-
-
-
-
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
-
-
-
-
-
-
-
Zenas BioPharma (ZBIO) Appoints Haley Laken as Chief Scientific Officer
-
1,187,941 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

